Organization of the Book

*AHFS Drug Information®* (AHFS DI®) is a collection of drug monographs on virtually every single-drug entity available in the United States. *AHFS Drug Information®* is a tested and proven source of comparative, unbiased, and evaluative drug information.

AHFS DI® monographs are written principally on single-drug entities; information on various trademarked preparations and brands of a drug is contained in a single monograph. Drug *combinations* are described in the monographs on the principal ingredients or, rarely, appear as separate monographs (e.g., Co-trimoxazole 8:12.20) when the combinations are considered important because of therapeutic rationale and/or frequency of use. There also are general statements on groups of drugs (e.g., Salicylates 28:08.04.24) whose activities and uses permit their discussion as a class.

Information on older and prototype drugs is another feature of AHFS DI®. Drug monographs are arranged by the widely recognized and used AHFS® Pharmacologic-Therapeutic Classification®. (See p. viii.) This arrangement permits easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group.

A *table of contents* precedes each major class of drugs (e.g., 8:00 Anti-infective Agents) in the book. The table of contents lists each drug monograph included in that major class according to the specific subclass (e.g., Cephalosporins 8:12.06). Within each subclass, monographs are arranged alphabetically by nonproprietary (generic) name and are preceded by the general statement, when present, for that subclass. The names of the drugs are the United States Adopted Names (USAN) and other names for drugs as described in the *USP Dictionary of USAN and International Drug Names*.

Because of the unique arrangement of the book, information on a particular drug can be located by several methods. Information can be located via the Index by using any of the following index terms:
- proprietary (trade) name
- nonproprietary (generic) name
- synonym (e.g., British Approved Name [BANI])
- abbreviation (e.g., INH for isoniazid)
- pharmacy equivalent name (PEN) (e.g., co-triamepramide for the fixed combination of hydrochlorothiazide and triamterene)
- former name (e.g., glyceryl guaiacolate for guaiifenesin)

The Index also includes entries for all AHFS® Pharmacologic-Therapeutic Classification® terms; therefore, a specific class of drugs (e.g., cephalosporins) can be located by referring to the Index. Once the table of contents for a specific major class of drugs has been located, the page number for the beginning of each drug monograph is listed alongside the monograph title in the table; thus, the list of drug monographs in a given subclass can be quickly scanned to locate a specific drug or drugs of interest. Synonyms for drug classes and other cross-references for classes of drugs (e.g., ACE inhibitors) also may be included in the Index.

Some monographs have been omitted from the print version of AHFS DI® because of space limitations. Associated index entries and listings in the table of contents for each major class of drugs in the printed book refer users to the website www.ahfsdruginformation.com to see these monographs. A username and password are required to access these electronic-only monographs. (See the Preface for information on subscriber access to this website.) Each year after publication of the print edition of AHFS DI®, new monographs are created, and revisions to existing monographs continue. At the end of the subscription year, any new or revised monographs that were published electronically usually will become incorporated into the upcoming annual edition of AHFS DI® within the appropriate AHFS Pharmacologic-Therapeutic class®. Such revised monographs carry the statement “Selected Revisions January 2017” or some other appropriate revision date in the Copyright notice at the end of the monograph. Because information about a drug frequently changes, the manufacturer’s labeling should be reviewed periodically.

### Organization of Full-length Monographs

Information within each drug monograph is divided into the following sections and subsections:
- Monograph Title and Synonyms
- REMS
- Introductory Description
- Uses
- Dosage and Administration
- Cautions
- Adverse Effects
- Precautions and Contraindications
- Pediatric Precautions
- Geriatric Precautions
- Mutagenicity and Carcinogenicity
- Pregnancy, Fertility, and Lactation
- Drug Interactions
- Laboratory Test Interferences
- Acute Toxicity
- Pathogenesis
- Manifestations
- Treatment
- Chronic Toxicity
- Pathogenesis
- Manifestations
- Treatment
- Pharmacology
- Mechanism of Action (for anti-infectives)
- Spectrum (for anti-infectives)
- Resistance (for anti-infectives)
- Pharmacokinetics
- Absorption
- Distribution
- Elimination
- Chemistry and Stability
- Chemistry
- Stability
- Preparations

Not all sections or subsections are included in each monograph. The information is divided only when applicable and necessary. Other subsections not listed above also are used within Pharmacology, Uses, Cautions, and Dosage and Administration.

The presence or absence of a particular drug or use should not be interpreted as indicating any judgment by AHFS DI® on its merits.

Described below are the types of information that may be included in each major section and subsection within a monograph. Individual monographs may not contain all of the information described below, and the absence of specific information within an individual monograph does not imply that such information is unavailable.

#### Monograph Title and Synonyms

Lists the USAN name or other name for the drug(s) described; salts generally are included even when omitted from the USAN name. If multiple forms (e.g., salts, esters) of the same drug are available, all forms are described within the monograph; the title may include all forms (if only a few) or just the base (active moiety).

Occasionally, when several drug entities are described in a single monograph, an alternative title descriptive of the group (e.g., Antacids 56:64) is used. Common synonyms for the drug are listed alongside the USAN or other names. When a graphic formula of the drug or prototype (if multiple drugs) is present, it is in the style adopted by the USAN Council and United States Pharmacopoeial Convention.

Occasionally, certain synonyms (e.g., pharmacy equivalent names [PENs]) that apply to specific preparations or combinations rather than to the drug itself are noted parenthetically alongside various preparation headings. (See the discussion on Preparations.)

#### Introductory Description

Provides a brief chemical, structural, and/or pharmacologic/therapeutic description for the purpose of orientation and introduction.

#### REMS

Provides a brief description of a Risk Evaluation and Mitigation Strategy (REMS) approved by the US Food and Drug Administration (FDA), including a list of the components. Because REMS frequently are modified or rescinded, a cross reference to FDA’s list of “Approved Risk Evaluation and Mitigation Strategies (REMS)” is provided to refer users to the most current information. REMS for drug combinations are described in the monographs on the principal ingredient.

#### Uses

Provides information on uses included in the labeling approved by FDA and those that are not (i.e., “off-label” [unlabeled] uses). Off-label uses are identified with daggers† within the text of the monograph; a footnote that describes the use as unlabeled appears at the end of the monograph. Comparisons with other forms of therapy and limitations on use are included when appropriate. This section usually is subdivided by major indication.

Under the Federal Food, Drug, and Cosmetic (FD&C) Act, the labeling approved by FDA for a drug is limited to those uses for which the sponsor has submitted.
information regarding the safety and efficacy of that product and which has been reviewed by the FDA; other uses for which the sponsor has chosen not to submit data to the FDA may be demonstrated in the clinical literature before and after the product is approved by FDA. The FD&C Act does not, however, limit the manner in which a clinician may use an approved drug. Once a drug has been approved for marketing, the clinician may prescribe it for uses or in treatment regimens or patient populations (e.g., children) that are not included in approved labeling. Such off-label uses may be appropriate and rational, and may reflect approaches to drug therapy that have been reported extensively in the medical literature. Valid new uses for drugs often are first discovered via serendipitous observations and therapeutic innovations, and then subsequently may be confirmed by well-designed and controlled studies. Inclusion of such new uses in the FDA-approved labeling for a drug may take considerable time and, without the initiative of the sponsor whose product is involved, may never occur. Therefore, accepted medical practice (state-of-the-art) often includes drug use that is not included in FDA-approved labeling. Accordingly, AHFS DI® monographs attempt to describe most uses for a drug, whether or not they are included in FDA-approved labeling; however, the presence or absence of a particular use should not be interpreted as indicating any judgment by AHFS DI® on its merits. Coverage of off-label uses in AHFS Drug Information®, an official Federal drug compendium, has been recognized by the US Congress (e.g., in OBRA 90 and OBRA 93), the Centers for Medicare & Medicaid Services (CMS; Section 1861 and 1927 of the Social Security Act), third-party health-care providers, and others. (See Off-label Uses at http://www.afhsdruginformation.com for additional information.)

AHFS DI® is the only remaining official drug compendium published by a non-commercial, nonprofit professional and scientific society. ASHP is an IRS 501(c)(6) tax-exempt entity.

Drugs designated as orphan drugs by FDA and those otherwise considered as orphans are described. An orphan drug is one that is used for the treatment of a rare disease or condition that either occurs in fewer than 200,000 individuals in the US or is more prevalent but for which there is no reasonable expectation that the cost of developing and marketing the drug in the US for such disease or condition would be recovered from US sales. An orphan drug also may be a vaccine, diagnostic drug, or preventive drug if the individuals to whom it will be administered in the US are fewer than 200,000 per year.

AHFS Grades of Recommendation

During 2008, AHFS DI® introduced a new process for publishing structured, codified, evidence-based determinations for off-label cancer uses. In some monographs that subsequently were revised based on Final Off-label Determinations for cancer uses, text describing such uses based on AHFS Grades of Recommendation may be noted. Following are the categories of AHFS Grades of Recommendation and the definitions of each:

- A: Recommended (Accepted) (e.g., should be used, is recommended/indicated, is useful/effective/beneficial in most cases)
- B: Reasonable Choice (Accepted, with Possible Conditions) (e.g., treatment option) (e.g., is reasonable to use under certain conditions [e.g., in certain patient groups], can be useful/effective/beneficial, is probably recommended/indicated)
- C: Not Fully Established (Unclear risk/benefit, equivocal evidence, inadequate data and/or experience) (e.g., usefulness/effectiveness unknown/unclear/un certain or not well established relative to standard care)
- D: Not Recommended (Unaccepted) (e.g., considered inappropriate, obsolete, or unproven: is not useful/effective/beneficial, may be harmful)

Documents describing the current process for off-label oncology uses, including levels of evidence, may be viewed under the Off-label Uses section of the AHFS DI® website at http://www.afhsdruginformation.com. Subscribers may access details about specific determinations of medical acceptance for these uses at this website location.

Dosage and Administration

Includes information on reconstitution and administration of specific dosage forms and on dosage. In addition, restricted distribution programs for certain drugs may be described when requirements for prescribing and dispensing a drug exist or where distribution is otherwise limited (e.g., orphan drugs).

The Administration subsection describes the routes of administration and, when necessary for clarity, the appropriate dosage form for each route. Instructions for administering the drug (e.g., after meals, with food) and specialized methods of administration are given. Occasionally, instructions for extemporaneous preparation of a dosage form that is not commercially available (e.g., preparation of a pediatric oral suspension from the contents of capsules) are included. For injectable drugs or other dosage forms requiring reconstitution, the Administration subsection is replaced by the Reconstitution and Administration subsection. In addition to information described for the Administration subsection, instructions for reconstitution and, when applicable, further dilution of the dosage form are presented. The rate of injection or infusion of the drug is described, as well as any precautions associated with administration. Generally, compatibility and stability information is described under Chemistry and Stability.
are described. Plasma concentrations associated with toxicity are included when well described.

Recommendations for management of acute toxicity, including those for supportive and symptomatic treatment, are described.

### Pharmacokinetics

Describes absorption, distribution, and elimination (biotransformation and excretion) characteristics of a drug.

The Absorption subsection includes information on extent (bioavailability) and rate of absorption by usual routes of administration and factors (e.g., product formulation) that might influence them. Applicable comparative information on doses, dosage forms, and routes of administration is included. Information on serum concentrations achieved and on the period of time for onset, peak, and duration of pharmacologic and/or therapeutic effect also is included, even when an absorption phase per se does not occur (e.g., following IV administration). Ranges for therapeutic and/or toxic concentrations (e.g., plasma, serum) of the drug are described when established.

The Distribution subsection describes the usual distribution of the drug into body tissue and fluids. Information describing the drug’s propensity to cross the blood-brain barrier and placenta and to distribute into milk is included. Protein binding characteristics are presented.

The Elimination subsection describes the biotransformation and excretory characteristics of the drug. Information on elimination half-life and factors influencing it, clearance, site and extent of biotransformation, metabolic products and their activities, and routes of elimination from the body (e.g., urine, feces via bile) and factors affecting them is included. The effect of peritoneal dialysis and hemodialysis on elimination of the drug also is discussed.

### Chemistry and Stability

Includes a brief chemical, structural, and/or pharmacologic description, often compared with other similar drugs, for the purpose of orientation and introduction. Structure-activity relationships are described when applicable. A physical description of the drug entities includes physical appearance, taste, odor, and solubility. Solubilities are described according to USP descriptive terms (see the current edition of the United States Pharmacopoeia–National Formulary [USP–NF]) or as appropriate specific solubilities (i.e., amount of solute per volume of solvent).

If the drug is ionizable, the pK\(_a\) is given. Other chemical and/or physical constants such as pH and osmolarity/osmolality of commercially available preparations are included. Preservatives and other important excipients in a commercial preparation also are described. Dosage equivalences (e.g., units per mg of drug, mg of base per mg of salt) are given when the dosage of a drug differs from the commercially available form (e.g., salt, ester). Amounts of important ions (e.g., mg/mEq of potassium, sodium) in commercial preparations also are included.

Applicable stability information such as the effect of pH, autoclaving, heat, light, moisture, air, freezing, and microwave thawing is described. Storage requirements (i.e., recommended environmental storage conditions) also are described. Stability information about reconstituted and/or diluted preparations is provided. Physical and/or chemical compatibility information may be included. Additional detailed compatibility information on injectable drugs is available in the *Handbook on Injectable Drugs* (available from the American Society of Health-System Pharmacists; go to www.ashp.org for details).

### Preparations

Lists commercially available preparations of the drug. Preparations are described under the appropriate heading by USAN or other proprietary (generic) name. Combination preparations are described under a separate heading (e.g., Aspirin Combinations) following the appropriate single-entity subsection (e.g., Aspirin); official USP combination names (e.g., Metoprolol Tartrate and Hydrochlorothiazide) also are used whenever possible.

Preparations are listed hierarchically by route of administration (alphabetically, dose form [alphabetically], and strength) in order of increasing strength. When potency is described in terms other than those listed in the drug heading (e.g., potency of cefotaxime sodium is expressed in terms of cefoxatime), the labeled moiety is described parenthetically after the strength [e.g., 1 g (of cefotaxime)]. Although USP has changed its naming conventions to eliminate salt forms in many official monograph titles (active moiety nomenclature concept), the American Society of Health-System Pharmacists continues to oppose this nomenclature change because of resulting confusion and loss of important chemical identity cues, and therefore AHFS DI will continue to include salts in the Preparations headings for clarity.

Route of administration and dosage form listings may be modified (e.g., Injection, for IM use only; Tablets, chewable; Capsules, extended-release). Following each preparation description, the proprietary (trade) names are listed alphabetically and include the corresponding manufacturers. Generally, multiple-source preparations that are available by nonproprietary (generic) name do not include the manufacturers/labelers; these preparations are described as being “available by nonproprietary name.”

When established by USP, pharmacy equivalent names (PENs) (e.g., co-careldopa for levodopa and carbidopa) are listed parenthetically alongside the corresponding combination heading. PENs are short and simple names that can be used for convenience by practitioners when it would be impractical to use the complete nonproprietary combination name. PENs are informational rather than official (USP–NF), but are offered by USP as standardized terms intended to discourage the proliferation of trivial names and undefined abbreviations for combinations. This
demonstrate a risk to the fetus in the first trimester and there is no evidence of risk in
replacing the letters with a narrative structure for pregnancy labeling. Therefore, some
in Overviews. However, as noted previously FDA amended the requirements for
Pregnancy Precautions
interferences, and acute toxicity. cautions, precautions, contraindications, potential drug interactions, laboratory test

do not provide full disclosure about the respective drugs, and therefore it is essential
populations, common adverse effects), drug interactions, and important advice for
uses and associated dosages, product availability, selected cautionary information
e.g., review articles), and a limited number of primary references (e.g., the principal clinical studies) also may be included; however, the
overviews are not intended to be comprehensive. When additional information on
such drugs is needed before publication of a more detailed (full-length) AHFS DI® monograph, the manufacturer’s labeling should be consulted.

The Overviews are intended to provide subscribers to AHFS DI® with summaries on new molecular entities that can answer most common questions about these drugs. As such, the Overviews are limited to basic information on the drugs, including brief descriptions (chemical and pharmacologic) of the type of drug, its labeled uses and associated dosages, product availability, selected cautionary information (e.g., warnings and precautions, sensitivity reactions, cautions applicable to specific populations, common adverse effects), drug interactions, and important advice for patients. While selected precautionary information appears in these summaries, the scope of the overview format limits the extent of discussion. As a result, the Overviews do not provide full disclosure about the respective drugs, and therefore it is essential that the manufacturer’s labeling be consulted for more detailed information on usual cautions, precautions, contraindications, potential drug interactions, laboratory test interferences, and acute toxicity.

Pregnancy Precautions

The pregnancy precautions in the Overviews historically have followed FDA’s lettered categories (A, B, C, D, or X), as stated in the manufacturer’s labeling. Because of the summary format of the Overviews, only the letter designation usually appears in Overviews. However, as noted previously FDA amended the requirements for pregnancy and lactation labeling in 2014, eliminating these lettered categories and replacing the letters with a narrative structure for pregnancy labeling. Therefore, some AHFS DI® Overviews now contain text descriptions of information about use of a drug during pregnancy when the lettered category has not been provided in the labeling. Following are definitions of the categories FDA previously had designated:

Category A
Adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in the first trimester and there is no evidence of risk in
later trimesters. If the drug were used during pregnancy, the possibility of fetal harm appears remote.

Category B
Either animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women or animal reproduction studies have shown an adverse effect (other than on fertility) but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in the first trimester and there is no evidence of risk in later trimesters. In either case, the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus. In the latter case, the drug should be used during pregnancy only when clearly needed.

Category C
Either animal reproduction studies have revealed evidence of an adverse fetal effect and there are no adequate and well-controlled studies in pregnant women or animal reproduction studies have not been performed and it is not known whether the drug can cause fetal harm when administered to pregnant women. In the first case, the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus. In the latter case, the drug should be used during pregnancy only when clearly needed.

Category D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or postmarketing experience or studies in humans, but the potential benefits from use of the drug in pregnant women may be acceptable in certain conditions despite the possible risks to the fetus. The drug should be used during pregnancy only in life-threatening situations or severe disease for which safer drugs cannot be used or are ineffective. When the drug is administered during pregnancy or if the patient becomes pregnant while receiving the drug, the patient should be informed of the potential hazard to the fetus.

Category X
The drug may (can) cause fetal toxicity when administered to pregnant women based on animal or human studies demonstrating fetal abnormalities or positive evidence of human fetal risk from adverse reaction data from investigational or postmarketing experience, or both, and the risk of use of the drug during pregnancy clearly outweighs any benefit (e.g., safer drugs or alternative therapies are available). Since the risks clearly outweigh any possible benefits in women who are or may become pregnant, the drug is contraindicated in such women. If the drug is inadvertently administered during pregnancy or if the patient becomes pregnant while receiving the drug, the patient should be informed of the potential hazard to the fetus.

SumMons®
Certain monographs in AHFS DI® are designated as SumMons® (summary monographs). This designation appears in a boldface footnote preceding the Preparations section of the monograph. SumMons® are summary descriptions about the respective drug, which include information that is drawn principally from the manufacturer’s labeling (package insert) and/or other pertinent information (such as secondary references [e.g., review articles] and a limited number of primary references [e.g., the principal clinical studies]); however, no attempt is made to be complete, and the information may not be evaluative. When additional information on such drugs is needed pending development and publication of a more detailed (full-length) AHFS DI® monograph, the manufacturer’s labeling should be consulted.

The summaries are intended to provide only basic information on the drugs, and therefore are limited to brief descriptions (chemical and pharmacologic) of the type of drug, its labeled uses and associated dosages, and product availability. While selected precautionary information occasionally may appear in these summaries, no attempt is made to be complete, and therefore it is essential that the labeling be consulted for detailed information on the usual cautions, precautions, and contraindications. Some SumMons® have been expanded to include a detailed Cautions section, but it remains essential that the labeling be consulted for information on potential drug interactions, laboratory test interferences, and acute toxicity for such expanded descriptions. Some SumMons® also have been expanded to include important “unlabeled/off-label” uses.

Copyright
AHFS monographs are copyrighted by the American Society of Health-System Pharmacists (ASHP), Inc., 4500 East-West Highway, Suite 900, Bethesda, MD 20814. All rights reserved.

Subscribers to AHFS Drug Information® are authorized to reproduce or retransmit AHFS monographs that are published only electronically on the ahfsdruginformation.com website, not to exceed the total number of paid subscriptions by the subscriber. For example, if a subscriber pays for 3 subscriptions (“copies”), then the subscriber is authorized to reproduce and distribute and/or retransmit a total of 3 copies of a given document. All material distributed as part of AHFS Drug Information®, including AHFS full-length monographs, Overviews, and SumMons®, is copyrighted. Reproduction, storage in a retrieval system, or transmission of any such material or any part thereof in any form or by any means except as authorized (see

AHFS Drug Information® 2017 • Page 4 of 5
Other Notices

For other notices of warning, see Notices on p. iii of the master volume issued in January of each year.